CRF Health Reveals eConsent Survey Results


eConsent adoption slated to increase by at least 30% CAGR for the next three years

Plymouth Meeting, PA – Driving participant interactivity, enhancing understanding and improving satisfaction will be the focus of eConsent strategies in 2017 and beyond, according to the results of a new ‘State of eConsent’ survey released today by CRF Health. The findings suggest that 55% of respondents’ organizations will adopt eConsent in 2017, rising to 82% by 2020.

The survey, which collated the opinions of respondents from 100 biotech, pharmaceutical, CRO and IRB organizations, sought to benchmark eConsent use across the industry; to gauge experiences and expectations; better understand adoption hurdles and challenges; and predict how the use of eConsent will grow in the future. The 146 respondents included individuals from across clinical operations, executive leadership, clinical sciences and data management.

Other findings included that 76% of respondents view the ability to create the eConsent in-house without vendor involvement as one of the top design functionalities, and 80% specified that the ability to deploy eConsent to sites using digital tablets is a key priority. According to the results, perceived high costs and uncertain ROI are still proving to be a barrier and preventing some organizations from becoming early adopters.

“eConsent has quickly made a name for itself as the next big technology innovation for clinical trials,” comments Rachael Wyllie, CEO, CRF Health. “Both regulators and industry groups advocate the clear advantages of electronic means, so it is no surprise that sponsors and CROs are engaging with or are planning an eConsent initiative in the near future.

“The findings from the survey put the spotlight on the need for more adaptable solutions that don’t require continuous vendor support. This is going to be critical in helping customers build a strategic roadmap towards eConsent. Sponsors, CROs and sites are already suffering the burden of trying to integrate multiple and highly complex technologies into their trial designs. When it comes to eConsent, we’ve learned that our customers are looking for intuitive and easy-to-use solutions that ultimately achieve better data and better informed patients who remain in the clinical trial for its duration.”

To view the complete research findings, please visit

For more information on CRF Health, please visit www.crfhealth.comAbout CRF Health
CRF Health is the leading provider of patient-centered eSource and telemedicine technologies and service solutions for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages and across 74 countries, CRF Health’s TrialMax platform consistently demonstrates the industry’s highest data accuracy, patient and site compliance, and patient retention. Its recent acquisition of mHealth provider Entra Health, has allowed CRF Health to extend the connectivity of its existing technology to now include cloud-based remote patient monitoring, telehealth, data exchange and analytics.

CRF Health’s eSource solutions improve trial engagement by making the patient the center piece of the healthcare and clinical trial process, and seamlessly integrating into sites to maximize protocol compliance. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent, an electronic solution for collecting informed consent in clinical trials.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.